Angela O'Neill
PCR e-Course 2020: Sham patients from RADIANCE-HTN SOLO who crossed over...
Patients who crossed over from the sham control arm of the RADIANCE-HTN SOLO trial to the renal denervation arm after 12 months of elevated...
PCR e-Course 2020: Treatment with transcatheter bariatric embolotherapy results in greater...
Transcatheter bariatric embolotherapy (TBE) for obesity is safe and leads to clinically significant weight loss in comparison to a sham procedure, a hotline and...
Live webinar on Thursday 2 April to share COVID-19 cardiovascular experience
The Imperial College Network of Excellence in Vascular Science at Imperial College London (UK) is to run a COVID-19 Cardiovascular Conference as a live...
Virtual ACC: Combining aspirin with rivaroxaban reduces risk equally in presence...
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral endpoints in patients...
Virtual ACC: Aspirin plus rivaroxaban significantly lowers adverse events in PAD...
Treatment with aspirin plus rivaroxaban following lower extremity revascularisation in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk...
Adapt clinical studies to alleviate effect of pandemic
A viewpoint in the Journal of the American Medical Association (JAMA) has offered potential solutions to modifying ongoing randomised clinical trials during the COVID-19...
CDRH adjusts working practices with medical device companies to deal with...
The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) has written to the medical device industry to outline its...
TARGET BP I trial enrols its first patient
The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use...
